---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-072258"
form_type: "8-K"
ticker: "OCUL"
cik: "0001393434"
company_name: "OCULAR THERAPEUTIX, INC"
filed_at: "2023-06-16T23:59:59+00:00"
generated_at: "2026-06-13T22:27:03.158159+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Ocular Therapeutix shareholders approve 3.9M share increase under 2021 Stock Incentive Plan

## Summary
- Approved Amendment No. 2 increasing shares under 2021 Stock Incentive Plan by 3.9M (29.4M for, 8.0M against).
- Elected Jeffrey S. Heier, M.D. and Merilee Raines as Class III directors until 2026 annual meeting.
- Ratified PricewaterhouseCoopers as independent auditor for FY 2023 (60.5M for, 43K against).
- Non-binding advisory vote on named executive officer compensation passed (26.5M for, 11.2M against).

## SEC filing metadata
- accession: 0001104659-23-072258
- form_type: 8-K
- ticker: OCUL
- cik: 0001393434
- company_name: OCULAR THERAPEUTIX, INC
- filed_at: 2023-06-16T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1393434/000110465923072258/0001104659-23-072258-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1393434/000110465923072258/tm2318782d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-072258
- JSON: https://secwatch.observer/filing/0001104659-23-072258.json
- Plain text: https://secwatch.observer/filing/0001104659-23-072258.txt

## Key facts
- Shareholder Votes
  OCULAR THERAPEUTIX, INC shareholders approved Election of Class III directors.
  - Proposal: director election
  - Outcome: passed
  source text: The Company’s stockholders elected Jeffrey S. Heier, M.D. and Merilee Raines as Class III directors to serve until the 2026 Annual Meeting of Stockholders, each such director to hold office until his or her successor has been duly elected and qualified.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1393434/000110465923072258/0001104659-23-072258-index.htm
- Shareholder Votes
  OCULAR THERAPEUTIX, INC shareholders approved Non-binding advisory proposal regarding compensation of named executive officers.
  - Proposal: say on pay
  - Outcome: passed
  source text: The Company’s stockholders approved a non-binding, advisory proposal regarding the compensation of the Company’s named executive officers.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1393434/000110465923072258/0001104659-23-072258-index.htm
- Shareholder Votes
  OCULAR THERAPEUTIX, INC shareholders approved Amendment No. 2 to increase shares under the 2021 Stock Incentive Plan by 3,900,000 shares.
  - Proposal: equity plan
  - Outcome: passed
  source text: The Company’s stockholders approved Amendment No. 2 to increase the number of shares of common stock of the Company issuable under the 2021 Stock Incentive Plan by 3,900,000 shares.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1393434/000110465923072258/0001104659-23-072258-index.htm
- Shareholder Votes
  OCULAR THERAPEUTIX, INC shareholders approved Ratification of PricewaterhouseCoopers LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-12-31 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2023-12-31
  source text: The Company’s stockholders ratified the selection of PricewaterhouseCoopers LLP as its independent registered public accounting firm for the fiscal year ending December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1393434/000110465923072258/0001104659-23-072258-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.